Andrew Lo - 20 Jun 2025 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
Director
Signature
/s/ Andrew W. Lo, Ph.D.
Issuer symbol
BBIO
Transactions as of
20 Jun 2025
Transactions value $
$0
Form type
4
Filing time
24 Jun 2025, 19:13:23 UTC
Previous filing
16 Jun 2025
Next filing
19 Nov 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lo Andrew Director C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR., SUITE 250, PALO ALTO /s/ Andrew W. Lo, Ph.D. 24 Jun 2025 0001679076

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Award $0 +6.59K +13.7% $0.00 54.7K 20 Jun 2025 Direct F1, F2
holding BBIO Common Stock 106K 20 Jun 2025 By Andrew W. Lo and Nancy N. Lo JTWROS

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (Right to Buy) Award $0 +8.43K $0.00 8.43K 20 Jun 2025 Common Stock 8.43K $41.73 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.
F2 Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F3 One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.